{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:03:08Z","timestamp":1787770988492,"version":"build-2784847793"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BJC Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ixabepilone may retain activity in paclitaxel-resistant disease. We previously reported improved response rates (ORR), progression-free (PFS), and overall survival (OS) conferred by ixabepilone+bevacizumab (IXA\u2009+\u2009BEV) compared to monotherapy (IXA) in heavily pre-treated ovarian cancers. We now describe a mature data set. Subset analyses were performed in patients with different taxane sensitivities and dose modifications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients previously treated with paclitaxel were stratified by prior BEV and randomized to receive IXA 20\u2009mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      days 1,8,15\u2009\u00b1\u2009BEV 10\u2009mg\/kg days 1,15 of a 28-day cycle in a multi-site prospective randomized phase 2 trial.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty-seven patients were randomized to IXA and 39 patients to IXA\u2009+\u2009BEV. At the final data cutoff (05\/27\/2023), ORR was higher in the IXA\u2009+\u2009BEV arm (38.4% vs. 8.1%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003). Dose reductions were necessary in most participants but did not diminish PFS\/OS benefits. Most patients were paclitaxel-refractory\/-resistant (51%,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200919\/37;67%,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200926\/39); the remainder were taxane-sensitive. The addition of BEV to IXA conferred benefit in PFS (5.5 vs. 2.2 mo; HR 0.31, 90%CI 0.20\u20130.49,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and OS (10.3 vs. 6.0\u00a0mo; HR 0.56, 90%CI 0.38\u20130.84,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02) that persisted after adjusting for prior taxane response.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>IXA\u2009+\u2009BEV has activity in heavily pre-treated ovarian cancers and offers significant improvement in ORR and PFS\/OS compared to IXA, despite prior taxane response and dose reductions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>NCT03093155<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s44276-024-00067-5","type":"journal-article","created":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T07:04:57Z","timestamp":1718867097000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Randomized phase II trial of weekly ixabepilone \u00b1 biweekly bevacizumab for platinum-resistant or refractory ovarian\/fallopian tube\/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses"],"prefix":"10.1038","volume":"2","author":[{"given":"Dana M.","family":"Roque","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric R.","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Buza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Bellone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria S.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Altwerger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaagn","family":"Andikyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Azodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam G.","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ratner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro D.","family":"Santin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,20]]},"reference":[{"key":"67_CR1","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","volume":"21","author":"RF Ozols","year":"2003","unstructured":"Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194\u2013200.","journal-title":"J Clin Oncol"},{"key":"67_CR2","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Ovarian, Fallopian Tube, Primary Peritoneal Cancer v2.2023. 2023. Available from: https:\/\/www.nccn.org\/"},{"key":"67_CR3","doi-asserted-by":"publisher","first-page":"3836","DOI":"10.1200\/JCO.2015.63.1408","volume":"33","author":"AM Poveda","year":"2015","unstructured":"Poveda AM, Selle F, Hilpert F, Reuss A, Savarese A, Vergote I, et al. Bevacizumab combined with weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized Phase III AURELIA trial. J Clin Oncol 2015;33:3836\u20138,.","journal-title":"J Clin Oncol"},{"key":"67_CR4","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","volume":"32","author":"E Pujade-Lauraine","year":"2014","unstructured":"Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J, Clin Oncol 2014;32:1302\u20138.","journal-title":"J, Clin Oncol"},{"key":"67_CR5","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1002\/ijc.33395","volume":"148","author":"R Kessous","year":"2021","unstructured":"Kessous R, Wissing MD, Laskov I, Abitbol J, Bitharas J, Agnihotram VR, et al. Multiple lines of chemotherapy for patients with high-grade ovarian cancer: Predictors for response and effect on survival. Int J Cancer. 2021;148:2304\u201312.","journal-title":"Int J Cancer"},{"key":"67_CR6","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/S1470-2045(19)30029-4","volume":"20","author":"KN Moore","year":"2019","unstructured":"Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019;20:636\u201348.","journal-title":"Lancet Oncol"},{"key":"67_CR7","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.3390\/cancers12113323","volume":"12","author":"SM Maloney","year":"2020","unstructured":"Maloney SM, Hoover CA, Morejon-Lasso LV, Prosperi JR. Mechanisms of Taxane resistance. Cancers. 2020;12:3323.","journal-title":"Cancers"},{"key":"67_CR8","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41420-021-00554-5","volume":"7","author":"EV Sazonova","year":"2021","unstructured":"Sazonova EV, Kopeina GS, Imyanitov EN, Zhivotovsky B. Platinum drugs and taxanes: Can we overcome resistance? Cell Death Discov. 2021;7:155.","journal-title":"Cell Death Discov"},{"key":"67_CR9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s00280-008-0724-8","volume":"63","author":"FYF Lee","year":"2008","unstructured":"Lee FYF, Borzilleri R, Fairchild CR, Kamath A, Smykla R, Kramer R, et al. Preclinical discovery of ixabepilone, a highly active antineoplastic agent. Cancer Chemother Pharmacol 2008;63:157\u201366.","journal-title":"Cancer Chemother Pharmacol"},{"key":"67_CR10","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1158\/1078-0432.298.11.1","volume":"11","author":"S Mozzetti","year":"2005","unstructured":"Mozzetti S, Ferlini C, Concolino P, Filippetti F, Raspaglio G, Prislei S, et al. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res. 2005;11:298\u2013305.","journal-title":"Clin Cancer Res"},{"key":"67_CR11","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1038\/s41416-022-01717-6","volume":"126","author":"DM Roque","year":"2022","unstructured":"Roque DM, Siegel ER, Buza N, Bellone S, Silasi DA, Huang GS, et al. Randomised phase II trial of weekly ixabepilone\u00b1biweekly bevacizumab for platinum-resistant or refractory ovarian\/fallopian tube\/primary peritoneal cancer. Br J Cancer. 2022;126:1695\u2013703.","journal-title":"Br J Cancer"},{"key":"67_CR12","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1200\/JCO.2009.24.1455","volume":"28","author":"K De Geest","year":"2010","unstructured":"De Geest K, Blessing JA, Morris RT, Yamada SD, Monk BJ, Zweizig SL, et al. Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study. J Clin Oncol 2010;28:149\u201353.","journal-title":"J Clin Oncol"},{"key":"67_CR13","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1200\/JCO.2000.18.14.2733","volume":"18","author":"CF Verschraegen","year":"2000","unstructured":"Verschraegen CF, Sittisomwong T, Kudelka AP, Guedes ED, Steger M, Nelson-Taylor T, et al. Docetaxel for patients with paclitaxel-resistant M\u00fcllerian carcinoma. J Clin Oncol 2000;18:2733\u20139.","journal-title":"J Clin Oncol"},{"key":"67_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"67_CR15","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649\u201355.","journal-title":"Am J Clin Oncol"},{"key":"67_CR16","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) | Protocol Development | CTEP [Internet]. [cited 2020 Nov 6]. Available from: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm"},{"key":"67_CR17","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.ygyno.2011.01.009","volume":"121","author":"DM O\u2019Malley","year":"2011","unstructured":"O\u2019Malley DM, Richardson DL, Rheaume PS, Salani R, Eisenhauer EL, McCann GA, et al. Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. Gynecol Oncol 2011;121:269\u201372.","journal-title":"Gynecol Oncol"},{"key":"67_CR18","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/nrclinonc.2010.120","volume":"7","author":"RD Baird","year":"2010","unstructured":"Baird RD, Tan DSP, Kaye SB. Weekly paclitaxel in the treatment of recurrent ovarian cancer. Nat Rev Clin Oncol 2010;7:575\u201382.","journal-title":"Nat Rev Clin Oncol"},{"key":"67_CR19","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.ygyno.2005.10.036","volume":"101","author":"M Markman","year":"2006","unstructured":"Gynecologic Oncology Group, Markman M, Blessing J, Rubin SC, Connor J, Hanjani P, et al. Phase II trial of weekly paclitaxel (80 mg\/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol 2006;101:436\u201340.","journal-title":"Gynecol Oncol"},{"key":"67_CR20","doi-asserted-by":"publisher","unstructured":"Gunderson C, Papaila A, Ding K, Jernigan A, Bedell S, Miller D, et al. Weekly paclitaxe for recurrent ovarian cancer: does weekly administration during primary therapy impact efficacy and toxicity at recurrence?. 2017 [cited 2023 Jan 14]. Available from: https:\/\/doi.org\/10.1016\/j.ygyno.2017.03.359","DOI":"10.1016\/j.ygyno.2017.03.359"},{"key":"67_CR21","unstructured":"Alicia O, Bodla, Shankar, Gore, Marin, Kaye, Stan, Banerjee, Susana. B59: Re-challenge with weekly paclitaxel in patients with advanced epithelial ovarian cancer, fallopian tube and primary peritoneal cancer. [Internet]. National Cancer Research Institute Cancer Conference; 2015 Nov 3 [cited 2023 Dec 17]. Available from: https:\/\/abstracts.ncri.org.uk\/abstract\/re-challenge-with-weekly-paclitaxel-in-patients-with-advanced-epithelial-ovarian-cancer-fallopian-tube-and-primary-peritoneal-cancer-ppc-2\/"},{"key":"67_CR22","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.ygyno.2020.08.032","volume":"159","author":"A Madariaga","year":"2020","unstructured":"Madariaga A, Garg S, Bruce JP, Thiryayi S, Mandilaras V, Rath P, et al. Biomarkers of outcome to weekly paclitaxel in epithelial ovarian cancer. Gynecol Oncol 2020;159:539\u201345.","journal-title":"Gynecol Oncol"}],"container-title":["BJC Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44276-024-00067-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44276-024-00067-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44276-024-00067-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T07:13:05Z","timestamp":1718867585000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44276-024-00067-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,20]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["67"],"URL":"https:\/\/doi.org\/10.1038\/s44276-024-00067-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4345163\/v1","asserted-by":"object"}]},"ISSN":["2731-9377"],"issn-type":[{"value":"2731-9377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,20]]},"assertion":[{"value":"29 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All patients provided written informed consent to participate in this study. The study was approved by each participating institution\u2019s Human Investigations Committee\/Institutional Review Board. This study was performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"43"}}